Literature DB >> 15583822

Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density.

Haneen Sadick1, Ramin Naim, Ulrich Gössler, Karl Hörmann, Frank Riedel.   

Abstract

Angiogenesis defines the physiologic process of capillary blood vessel formation. It is a multistep process, which is controlled by a large number of pro- and anti-angiogenic factors. Vascular endothelial growth factors (VEGF) are the best characterized pro-angiogenic factors, which play a key role in angiogenesis. Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant, multi-systemic disorder of angiogenesis, clinically characterized by severe and recurrent hemorrhages. We assume in HHT patients with increased VEGF plasma levels a high VEGF expression also correlates with the degree of microvesssel density (MVD). In 41 HHT patients and 47 healthy patients, the VEGF165 plasma concentration was determined by standard ELISA technique. Cryostat sections of 13 HHT patients were immunostained for VEGF and endothelial cells by an anti-vWF monoclonal antibody using a standard streptavidinbiotin complex procedure. The degree of vessel density was quantified by light microscopy (x200) within 'hot spot' areas of the HHT-tissue. All HHT cryostat sections showed a medium to strong staining for VEFG compared to healthy control tissue. The VEGF expression correlated with the VEGF165 plasma concentration and the mean MVD in HHT patients. HHT patients with medium VEGF staining revealed significantly lower VEGF165 plasma concentrations and a lower mean MVD (204+/-12 vessels/per microscopic field) than HHT patients with strong VEGF staining (327+/-76 vessels/per microscopic field). High VEGF expression in patients with HHT in correlation to their VEGF165 plasma levels and the microvessel density may support the theory that VEGF functions as an important regulator and key protein of angiogenesis, even in HHT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15583822

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  19 in total

Review 1.  Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia.

Authors:  Cameron Grigg; Daniel Anderson; James Earnshaw
Journal:  Ochsner J       Date:  2017

2.  Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis.

Authors:  Ni Wei; Zijia Chen; Zhifeng Xue; Yuelan Zhu
Journal:  Rheumatol Int       Date:  2015-05-26       Impact factor: 2.631

3.  Matrix Gla protein deficiency causes arteriovenous malformations in mice.

Authors:  Yucheng Yao; Medet Jumabay; Anthony Wang; Kristina I Boström
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

4.  Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in Endoglin heterozygous mice.

Authors:  Mirjana Jerkic; Madonna Peter; Daniela Ardelean; Michael Fine; Moritz A Konerding; Michelle Letarte
Journal:  Inflamm Bowel Dis       Date:  2010-11       Impact factor: 5.325

Review 5.  Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures.

Authors:  Haneen Sadick; Maliha Sadick; Karl Götte; Ramin Naim; Frank Riedel; Gregor Bran; Karl Hörmann
Journal:  Wien Klin Wochenschr       Date:  2006-03       Impact factor: 1.704

6.  The Impact on COVID-19 by Intravenous Bevacizumab Used for Hereditary Hemorrhagic Telangiectasia: A Case Report.

Authors:  Ryan Patrick Fanning; Sara Strout; Nicholas R Rowan; Clifford R Weiss; Panagis Galiatsatos
Journal:  J Med Cases       Date:  2022-06-02

7.  Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells.

Authors:  Esther S Shao; Laura Lin; Yucheng Yao; Kristina I Boström
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

8.  Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.

Authors:  Sung Ok Park; Mamta Wankhede; Young Jae Lee; Eun-Jung Choi; Naime Fliess; Se-Woon Choe; Seh-Hoon Oh; Glenn Walter; Mohan K Raizada; Brian S Sorg; S Paul Oh
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

Review 9.  Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia.

Authors:  Daniela S Ardelean; Michelle Letarte
Journal:  Front Genet       Date:  2015-02-11       Impact factor: 4.599

Review 10.  Pericytes as targets in hereditary hemorrhagic telangiectasia.

Authors:  Jérémy Thalgott; Damien Dos-Santos-Luis; Franck Lebrin
Journal:  Front Genet       Date:  2015-02-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.